Randomized PhaseII study of amrubicin vs platinum-doublet re-challenge for small cell lung cancer with sensitive relapse

Randomized PhaseII study of amrubicin vs platinum-doublet re-challenge for small cell lung cancer with sensitive relapse - AMR vs Re-Platinum for Sensitive Relapsed SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002617

Enrollment

Registered

2010-03-31

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small-Cell Lung Cancer

Interventions

amrubicin Re-challange of platinum-doublet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sensitive relapased SCLC after platinum-based chemotherapy ECOG performance status 0-2 Adequate organ function With mesurable lesion With written informed concent

Exclusion criteria

Exclusion criteria: Pre-treated with amrubicin With severe co-morbidities With symptomatic brain metastasis

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactAkira Inoue

Tohoku University Hospital Department of Respiratory Medicine

akinoue@idac.tohoku.ac.jp+81-22-717-8539

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026